LTRN Stock Overview
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Lantern Pharma Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$9.78 |
52 Week High | US$11.99 |
52 Week Low | US$2.38 |
Beta | 1.27 |
1 Month Change | 127.44% |
3 Month Change | 122.78% |
1 Year Change | 111.69% |
3 Year Change | -46.09% |
5 Year Change | n/a |
Change since IPO | -34.58% |
Recent News & Updates
Recent updates
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Feb 28We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate
Nov 06Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans
Jul 20We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Apr 04Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Dec 19We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Sep 02Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer
Jul 14Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth
May 20Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Feb 02We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Oct 13Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer
Aug 24Lantern Pharma: Drug Recycling With AI
Jun 08We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate
May 05Lantern Pharma reports Q1 results
May 03Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like
Feb 19Lantern Pharma announces antibody drug conjugate tie-up with Califia Pharma
Jan 04Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?
Dec 28Lantern: Early Stage 'Smart Drug' Discovery Company
Nov 25Shareholder Returns
LTRN | US Biotechs | US Market | |
---|---|---|---|
7D | 11.1% | 0.9% | 0.4% |
1Y | 111.7% | 10.3% | 28.8% |
Return vs Industry: LTRN exceeded the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: LTRN exceeded the US Market which returned 29.5% over the past year.
Price Volatility
LTRN volatility | |
---|---|
LTRN Average Weekly Movement | 20.4% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LTRN's share price has been volatile over the past 3 months.
Volatility Over Time: LTRN's weekly volatility has increased from 14% to 20% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 21 | Panna Sharma | https://www.lanternpharma.com |
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma.
Lantern Pharma Inc. Fundamentals Summary
LTRN fundamental statistics | |
---|---|
Market cap | US$105.05m |
Earnings (TTM) | -US$15.96m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.6x
P/E RatioIs LTRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LTRN income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$15.96m |
Earnings | -US$15.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.49 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did LTRN perform over the long term?
See historical performance and comparison